$CABA News

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

Cabaletta Bio to Participate in Upcoming Investor Conferences

Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate

How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune

Cabaletta Bio Q1 EPS $(0.39), Inline

Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target